加味芎归汤通过SUCNR1调控小胶质细胞极化改善阿尔茨海默病神经炎症
该研究探讨加味芎归汤(JWXG)是否通过靶向琥珀酸受体1(SUCNR1)介导的小胶质细胞极化来减轻阿尔茨海默病(AD)进展。在APP/PS1小鼠和Aβ刺激的BV-2小胶质细胞中,JWXG改善认知功能、减少Aβ沉积和神经炎症,并促进小胶质细胞从促炎向抗炎表型极化;Sucnr1敲除或敲低后JWXG疗效显著减弱,证实SUCNR1是其关键作用靶点。
要点
- JWXG可改善APP/PS1小鼠工作记忆与空间学习记忆能力。
- JWXG减少Aβ沉积并促进小胶质细胞向抗炎表型极化。
- SUCNR1敲除或敲低后JWXG的神经保护作用显著减弱。
核心结论
- JWXG通过调控SUCNR1介导的小胶质细胞极化减轻AD神经炎症并改善认知,SUCNR1为其潜在分子靶点。
研究设计与样本
- 体内采用APP/PS1小鼠给予JWXG治疗,评估认知、Aβ沉积、神经炎症标志物及小胶质细胞极化状态。
- 体外采用Aβ刺激的BV-2小胶质细胞研究JWXG对炎症级联和SUCNR1依赖性极化的调控。
- 机制验证采用Sucnr1敲除小鼠和siRNA介导的BV-2细胞Sucnr1敲低,均在Aβ攻击条件下进行。
主要发现
- JWXG显著改善APP/PS1小鼠Y迷宫自发交替率和Morris水迷宫表现,并减轻神经元丢失和海马变性。
- JWXG减少斑块沉积并增加Aβ斑块周围Iba1+小胶质细胞聚集,增强小胶质细胞清除Aβ。
- JWXG下调斑块相关小胶质细胞SUCNR1表达,抑制琥珀酸-MCT1-SUCNR1信号级联。
- JWXG促使小胶质细胞从促炎表型(CD86+、IL-1β+)向抗炎表型(CD206+、IL-10+)转变。
- Sucnr1-/-小鼠和si-Sucnr1 BV-2细胞中JWXG的治疗效应显著减弱,证实靶点特异性。
临床怎么用
- JWXG可能作为靶向SUCNR1调控小胶质细胞极化的AD治疗策略,但需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Succinate receptor 1 (SUCNR1) activation promotes microglial polarization, exacerbating Aβ deposition and neuroinflammation in Alzheimer's disease (AD). While Jiawei Xionggui decoction (JWXG), a traditional Chinese herbal formulation, demonstrates therapeutic potential by modulating microglial activity, its precise molecular mechanisms require further elucidation. OBJECTIVES: To investigate whether JWXG attenuates AD progression by targeting SUCNR1-mediated microglial polarization. METHODS: In vivo, JWXG was administered to APP/PS1 mice with subsequent evaluation of cognitive performance, Aβ deposition, neuroinflammatory markers, and microglial polarization states. Complementary in vitro studies employed Aβ-stimulated BV-2 microglia to examine JWXG's modulation of inflammatory cascades and SUCNR1-dependent polarization. Mechanistic validation was achieved through Sucnr1 knockout (Sucnr1-/-) mice and siRNA-mediated Sucnr1 knockdown in BV-2 cells, both under Aβ challenge conditions, confirming SUCNR1's essential role in mediating JWXG's therapeutic efficacy of AD. RESULTS: JWXG treatment significantly improved cognitive function in APP/PS1 mice, enhancing working memory (Y-maze spontaneous alternation rate) and spatial learning/memory (Morris-water-maze performance), while attenuating neuronal loss and hippocampal degeneration. JWXG administration markedly reduced Aβ burden through enhanced microglial clearance, evidenced by decreased plaque deposition and increased Iba1+microglial clustering around deposits. Mechanistically, JWXG suppressed SUCNR1-mediated neuroinflammation by downregulating plaque-associated microglial SUCNR1 expression, inhibiting the succinate-MCT1 (monocarborxylat transporter 1)-SUCNR1 signaling cascade, and shifting microglial polarization from pro-inflammatory (CD86+, IL-1β+) to anti-inflammatory (CD206+, IL-10+) phenotypes. Genetic validation using Sucnr1-knockdown models confirmed target specificity, as JWXG's therapeutic effects were significantly attenuated in Sucnr1-/- mice and si-Sucnr1 BV-2 microglia under Aβ exposure conditions. Strong correlations linked SUCNR1 expression with both Aβ burden and microglial polarization markers, establishing SUCNR1-driven microglial polarization as the critical mediator of JWXG's dual anti-neuroinflammatory and neuroprotective effects in Alzheimer's pathogenesis. CONCLUSION: This study provides the first evidence that JWXG mitigates Alzheimer's disease progression by modulating microglial polarization via SUCNR1, as mechanistically validated using Sucnr1⁻/⁻ gene knockout models. These findings reveal a novel molecular target through which a traditional Chinese medicine formulation may exert anti-neuroinflammatory effects in AD.
引用
- Liu Y, Yang H, Zhang S, et al. SUCNR1-driven microglial polarization: Jiawei Xionggui decoction as a therapeutic strategy for Alzheimer's-related neuroinflammation. Phytomedicine. 2026. PMID: 41747588. doi:10.1016/j.phymed.2026.157978
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。